Τρίτη 19 Απριλίου 2022

Subsequent anti-myeloma therapy after idecabtagene vicleucel treatment in patients with relapsed/refractory multiple myeloma: A single center analysis

alexandrossfakianakis shared this article with you from Inoreader

Blood Cancer Journal, Published online: 19 April 2022; doi:10.1038/s41408-022-00662-0

Subsequent anti-myeloma therapy after idecabtagene vicleucel treatment in patients with relapsed/refractory multiple myeloma: A single center analysis
View on the web

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Αρχειοθήκη ιστολογίου

a